Detalhe da pesquisa
1.
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Am J Hematol
; 95(6): 604-611, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32096887
2.
Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Leuk Lymphoma
; 64(5): 913-926, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37255002
3.
Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?
BMC Cancer
; 12: 210, 2012 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-22650448
4.
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cancer Med
; 9(22): 8468-8479, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32969597
5.
Pralatrexate, a new hope for aggressive T-cell lymphomas?
Clin Transl Oncol
; 11(4): 215-20, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19380298
6.
Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.
Leuk Lymphoma
; 59(5): 1095-1104, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28836866